Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
The end of high drug prices? Exploring the potential and limits of PDABs
Certain states in the US have enacted or are actively considering legislation to create PDABs, Prescription Drug Affordability Boards. PDABs are independent...